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abstRact
IntroductIon: Psychiatric disease is overlooked in drug 
users. Patients with both drug abuse and a psychiatric dis-
ease – dual diagnosis – suffer decreased compliance to 
treatment and decreased life expectancy compared with 
single-diagnosis patients. Identifying the patients among 
 either drug addicts or mentally ill patients is difficult.
Methods: All drug addicts autopsied at the Department of 
Forensic Medicine, University of Copenhagen, Denmark, in 
the years 1992, 2002 and 2012 were included. The group 
was divided into two subpopulations of possible dual diag-
nosis patients either according to police reports stating 
mental illness or to psychotropics found in the toxicology 
screening after autopsy.
results:  We found a rise in possible mental illness in both 
subpopulations in the study period. Drug addicts with psy-
chotropics in the blood at the time of death increased from 
3.1% in 1992 to 48.1% in 2012, and this group was signifi-
cantly younger at the time of death than those without 
 psychotropics in the blood. 
conclusIons: Suspected dual diagnosis patients have in-
creased in number. They die earlier than their drug addict 
counterparts. Methadone remains the leading cause of 
death in all subpopulations. Possible causes are misuse of 
treatment and/or illegally bought methadone, wrongly 
 assigned cause of death due to unknown tolerance and/or 
polydrug toxicity in combination with psychotropic medi-
cine.
FundIng: none.
trIal regIstratIon: not relevant.
Drug addicts and mentally ill patients have a markedly 
lower life expectancy than the general population [1, 2]. 
Dual diagnosis – the simultaneous occurrence of 
drug and/or alcohol use and a mental illness in a patient 
– is a different kind of challenge than suffering from ei-
ther one or the other for both the patient and for health 
personnel, social workers, families and friends. Suffering 
from a dual diagnosis leads to a further decreased treat-
ment compliance and an even more reduced life expect-
ancy compared with suffering from one diagnosis alone 
[2-4]. Unfortunately, this also seems to be true for dual 
diagnosis patients receiving substitution treatment for 
their drug use [5] and could be due to polydrug toxicity 
[6].
The number of patients with dual diagnosis has in-
creased in the past decades [7]. Numerous initiatives 
have been launched to improve treatment and quality of 
life and to decrease the mortality rate for these patients; 
however, a major challenge is to identify the group 
which could benefit from these initiatives. Identification 
has been attempted during the past 20 years with differ-
ent measures and different outcomes [3, 7, 8], either by 
describing drug abuse among admitted individuals or by 
describing psychiatric disorders within a population of 
drug addicts in out-patient treatment centres.
The dual diagnosis population increased from 8,000 
in 2000 to 11,000 in 2008, encompassing 10% of the en-
tire psychiatric population in Denmark [7]. Approx. 1,800 
dual diagnosis patients with severe psychiatric disorders 
and a minimum of 1,600 patients with lighter psychiatric 
disorders were admitted for psychiatric treatment dur-
ing the course of one year, either for out-patient or in-
hospital treatment [3].
In comparison, the most recent estimate of the 
number of drug users in Denmark is 33,000 out of 5.6 
million inhabitants (0.6%) [1]. It is estimated that – at 
any given time – the number of people who suffer from 
a mental illness of varying degrees comprises 10-20% of 
the population, whereas 2% of the population suffer 
from a long-lasting mental illness at any time [2].
Many of the estimates, including two of the most 
recent Danish studies [3, 7], focus on identifying dual 
diag nosis among living, mentally ill patients by use of 
registry-based analysis. This method is based on study-
ing psychiatric patients admitted or treated in open 
psych iatric facilities or hospitals and it focuses solely on 
the assessment of the population size and the challen-
ges for the healthcare system. Only one study focuses 
on identifying dual diagnosis patients among living drug 
addicts [9]. In Denmark, all deaths that are considered to 
be connected to drug abuse have been autopsied since 
1970 due to a decree from the Ministry of Justice [10]. 
This creates a unique collection of data on drug addicts 
in Denmark.
The three Danish departments of forensic medicine 
do not have access to patient files, but receive back-
ground information concerning deceased persons 
through police reports. This means that the doctor per-
forming the autopsy will have no information of any 
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mental illness unless this information has been given to 
the police prior to the autopsy.
Police reports rely on information from general 
practitioners whenever available, and on information 
from family members, friends or other people such as 
neighbours. Furthermore, police reports include a de-
scription of medicine found among the possessions of 
the deceased. 
Another possible predictor of mental illness may be 
the identification of psychotropic medication in the 
blood at the time of death, which may either be due to 
abuse or treatment; the latter indicating mental illness.
Through many years of research on drug addicts in 
Denmark, the most current being from 2014 [1], it is 
known that benzodiazepines are popular among drug 
addicts without mental illness and these are prescribed 
as part of their substitution treatment. Unfortunately, 
this makes it an unreliable marker for mental illness un-
less the diagnosis can be cross-referenced.
To our knowledge, no Danish or international  
studies analyse the prevalence of dual diagnosis cases in 
a deceased population with access to unique autopsy 
analyses.
Aims: The purpose of this study was to explore to 
which degree dual diagnosis can be identified in a popu-
lation consisting solely of identified, deceased and aut-
opsied drug addicts. By uncovering the number of de-
ceased drug addicts with a dual diagnosis – either 
through a reported psychiatric diagnosis in the police re-
port or the occurrence of psychotropic medication in the 
blood at the time of death – we may be able to further 
characterise this population. We therefore studied the 
cause of death in relation to single or dual diagnosis and 
explored trends during the past 20 years.
mEthOds
The material includes all drug addicts who were aut-
opsied at the Department of Forensic Medicine, Univer-
sity of Copenhagen, Denmark, in the years 1992, 2002 
and 2012. The cases were chosen from the department’s 
internal diagnosis system using the diagnosis of eupho-
mania and including all cases from the three years men-
tioned. The department of Copenhagen covers the east-
ern part of Denmark, which counts approx. 2.5 million 
inhabitants.
Death from poisoning involving more than one drug 
are listed after the drug considered the main contributor 
in the cause of death. All drugs found in the toxicology 
analysis are included and grouped into their respective 
major type of drug, including: antipsychotics, antide-
pressants, antiepileptics, benzodiazepines, methylpheni-
date and mood stabilisers. Heroin is listed as heroin/
morphine as heroin is degraded through several steps 
into morphine and cannot usually be isolated.
To identify any dual diagnosis patients, two sub-
populations were established based on police reports 
(subpopulation 1) and based on the presence of psycho-
tropics in the blood at the time of death, excluding ben-
zodiazepines (subpopulation 2).
Trial registration: not relevant.
REsUlts
In total, 290 deceased and autopsied drug addicts were 




Data from police reports suggested that in 1992, 21.6% 
(21/97) possibly had a psychiatric disorder or mental 
 illness, while the percentage rose to 41.4% (48/116) in 
2002 and to 41.6% (32/77) in 2012.
Subpopulation 2
From toxicology reports, we found that a total of three 
cases had psychotropic medication (excluding benzo-
diazepines) in the blood at the time of death, accounting 
for 3.1% (3/97) in 1992. In 2002, the share had increased 
to 31.0% (36/116) and in 2012 to 48.1% (37/77). More 
detailed information about the subpopulations is pre-
sented in Figure 1.
There is a significant association between subpo pu-
lation 1 and subpopulation 2 (chi-squared = 51.206, 
p < 0.005), meaning that there is an association between 
a police report stating a mental illness and the presence 
of psychotropic medicine in the toxicology screening.
Some characteristics of the entire group and the 
subpopulations are detailed in table 1. The mean age at 
the time of death of all deceased drug addicts has in-
creased; yet, subpopulation 2 died earlier than the non-
dual diagnosis group.
FigURE 1
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In the three years covered in this study, a total of 
218 died from poisoning with no apparent rise in the 
number throughout the period. Of these, 11 were regis-
tered with suicide as the manner of death and the re-
maining 207 were recorded as accidental poisoning/
overdose.
In subpopulation 1 (three years combined), 28.7% 
died from other causes than poisoning in comparison  
 to the non dual diagnosis drug addicts opposing sub-
popu lation 1, where 22.8% died from other causes. 
There is no significant difference between the two 
groups (chi-squared = 1.253, p > 0.05). 
In subpopulation 2, 21.1% died from other causes; 
within the remaining group, the percentage was 26.2%; 
no significant difference was found here either (chi-
squared = 0.786, p > 0.05). 
The other causes cover cardiovascular (4.5%), neu-
rological (3.4%), pulmonary (2.4%), and gastrointestinal 
(1%) causes. The remaining deaths were due to traumas 
and specific disorders. A total of 4.1% died from un-
known causes.
In general, the amount of psychotropic drugs and 
medications in the blood at the time of death increased 
in the 20-year study period. This increase could not be 
related to the number of established, fatal cases of poi-
soning as presented in table 2.
In total, 42.9% of all drug addicts in 2012 had psy-
chotropics in their blood, excluding benzodiazepines and 
antiepileptics. Looking at the 24 cases with antiepileptic 
medicine in their blood in 2012, there is an overlap; viz. 
11/24 (45.8%) had either antidepressants, antipsychot-
ics or methylphenidate in the blood as well. This means 
that up to 54.2% of the drug addicts in 2012 that only 
had antiepileptics in their blood could wrongly be as-
signed a dual diagnosis if they were undergoing epilepsy 
treatment.
table 3 presents the frequency of the two most 
common drugs causing fatal poisonings. The table dem-
onstrates that there is no significant difference between 
the subpopulations and that all groups share similar 
 patterns irrespectively of a positive police report or the 
presence of psychotropics in the blood.
Fatal methadone poisonings were more common in 
the group of drug users who received methadone as 
substitution treatment for their addiction: in this group 
the percentage rose to 77.8% in 2012 compared with 
61.3% in 2002 and 52.1% in 1992. However, the trend 
was not statistically significant (Mantel-Haenszel chi-
squared for linear trend = 0.6, p = 0.4).
discUssiOn
From 1992 to 2012, the number of possible mentally ill 
drug addicts increased in both subpopulations. Fatal poi-
sonings remain the leading cause of death in both 
groups, with methadone being the major contributor, 
and no difference was found between the populations. 
Death from other causes than poisoning was equally dis-
tributed across the subpopulations.
The aim of this study was not to distinguish acciden-
tal overdoses from suicides. Therefore, it is possible that 
part of the 200 deceased drug addicts dying from acci-
dental causes may, in fact, be due to intended overdos-
ing. Judging whether a case of overdose was accidental 
or intended is difficult and often relies on the presence 
of vital information of intent (prior history of suicidal be-
haviour and witness accounts), as well as on circumstan-
tial evidence such as suicide notes. If these are not pre-
sent, even suspected suicides will typically be declared 
accidental overdoses.
Fatal methadone poisonings in drug addicts being 
treated with methadone have increased with more than 
75% of drug addicts dying from methadone poisoning in 
2012. This makes it important to include drug addicts re-
ceiving substitution treatment when researching drug 
addicts with a dual diagnosis as they too die from fatal 
poisonings.
It must be underlined that the dose of methadone 
leading to death in patients who are being treated with 
the drug varies from case to case because of varying de-
grees of tolerance. Thus, deaths may occur even though 
the dose is within the treatment range, especially for 
drug-naïve subjects or after drug pauses. Furthermore, 
in most cases, several drugs are present, which stresses 
the importance of polydrug toxicity.
The mean age of drug addicts at the time of death 
has increased over time. Subpopulation 2 shows a sig-
nifi cant difference in age at the time of death. This is as-
Many deceased  
drug addicts may  
have been mentally ill.
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sociated with the presence of psychotropics, which re-
duces their lifespan. This demonstrates that even if we 
cannot be certain of the accuracy of the dual diagnosis, 
psychotropic medication is a risk and increases mortality 
in drug addicts.
There was a significant association between police 
reports stating mental illness in the deceased drug ad-
dicts and psychotropic medication found in the toxicol-
ogy screening. However, this was not a 100% match. The 
group of drug addicts not included in the subpopulations 
may still have been mentally ill; the diagnosis could have 
been omitted from witness accounts during the primary 
tablE 1
General characteristics. 1992
male female non-dual dual total
n (%) 76 (78.4) 21 (21.6) – – 97 (100)
Age, yrs, mean (range) 33 (20-48) 32 (20-48) – – 32.71 (20-48)
Poisoning as cause of death, n (%) 56 (73.7) 17 (81.0) – – 73 (72.5)
Age, yrs, mean ± SD (n)
Subpopulation 1 – – 32.04 ± 6.7 (76) 35.14 ± 7.3 (21) –
p-valuea 0.069
Subpopulation 2 – – 32.45 (94) 41.00 (3) –
p-valuea –b
SD = standard deviation. 
a) The independent samples t-test. 
b) Sample size too small for accurate testing. CONTINUES 
tablE 2
Psychotropics found in all 
deceased drug addicts, 
grouped by categories. 
The values are % (n).
 1992 2002 2012
Antidepressants   1.0 (1) 13.8 (16) 20.8 (16)
Antipsychotics   2.1 (2) 18.1 (21) 32.5 (25)
Antiepilepticsa   0.0 (0)   8.6 (10) 31.2 (24)
Mood stabilisers   0.0 (0)   0.9 (1)   0.0 (0)
Methylphenidate   0.0 (0)   0.0 (0)   2.6 (2)
Benzodiazepines 47.4 (46) 38.8 (45) 62.3 (48)
a) Includes a variety of drugs that can be used as stabilisers in psychotic 
patients; however, here we chose to group them according to their 
main purpose.
tablE 3
Major deadly poisonings sorted by the drug thought to be the major contributor (exact number of entries). 
1992 2002 2012 
non-dual dual total non-dual dual total non-dual dual total
Subpopulation 1
Patients, % (n/N) 76.3 (58/76) 71.4 (15/21) (73/97) 76.5 (52/68) 66.7 (32/48) (84/116) 80.0 (36/45) 78.1 (25/32) (61/77)
p-valuea 0.646 0.245 0.842
Drugs, % (n):
Methadone 32.8 (19) 40.0 (6) – 51.9 (27) 46.9 (15) – 88.9 (32) 76.0 (19) –
Heroin/morphine 62.1 (36) 53.3 (8) – 44.2 (23) 43.8 (14) –   8.3 (3) 16.0 (4) –
Other   5.2 (3)   6.7 (1) –   3.8 (2)   9.4 (3) –   2.8 (1)   8.0 (2) –
p-valuea 0.826 0.571 0.393
Subpopulation 2
Patients, % (n/N) 75.5 (71/94) 66.7 (2/3) – 70.0 (56/80) 77.8 (28/36) – 77.5 (31/40) 81.0 (30/37) –
p-valuea 0.726 0.386 0.699
Drugs, % (n):
Methadone 35.2 (25)   0.0 (0) – 48.2 (27) 53.6 (15) – 83.9 (26) 83.3 (25) –
Heroin/morphine 60.6 (43) 50.0 (1) – 46.4 (26) 39.3 (11) –   9.7 (3) 13.3 (4) –
Other   4.2 (3) 50.0 (1) –   5.4 (3)   7.1 (2) –   6.5 (2)   3.3 (1) –
p-valuea 0.017 0.809 0.787
Total
Drugs, % (n/N):
Methadone – – 34.2 (25/73) – – 50.0 (42/84) – – 83.6 (51/61)
Heroin/morphine – – 60.3 (44/73) – – 44.0 (37/84) – – 11.5 (7/61)
Other – –   5.5 (4/73) – –   6.0 (42/84) – –   4.9 (3/61)
a) Pearson’s chi-squared test.
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police investigation. It is also possible that some drug 
addicts had not been diagnosed or were diagnosed as 
mentally ill, but remained non-compliant to treatment. 
Likewise, non-diagnosed cases and cases that were not 
mentally ill may appear in the population due to self-
medication with prescription drugs bought illegally.
Finally, the toxicology screening shows only the 
 final picture and not the history leading to it.
In 1992, psychotropics were usually not present in 
the toxicology screening, but in 2012 psychotropics were 
found in one third of the population. The specific drugs 
in question are primarily the major groups of antide-
pressants, antipsychotics and antiepileptics; and they 
appear in all cases irrespective of the cause of death. 
Further studies are needed to determine why these 
drugs have such a prominent presence in the post mor-
tem toxicology screenings, and our findings raise the 
question if these drugs are prescribed more loosely or  
if they have entered the illegal drug market.
The use of psychotropic medication presents a vital 
risk factor as it increases the mortality among drug ad-
dicts even if we cannot be certain whether this is due to 
a dual diagnosis or to illegal use. The group with psycho-
tropic medicine in the blood has a significantly lower life 
expectancy than those in whom these medicines were 
absent. This creates an unfortunate dilemma where clin-
icians should be aware of possible underlying psychia tric 
disorders in drug addicts and provide the correct treat-
ment. Meanwhile, the use of psychotropic medication in 
the treatment of a dual diagnosis lowers the life span of 
drug addicts and provides them with substances that 
may be abused.
limitations of the study
The populations considered in this study are relatively 
small. The results presented here may therefore change 
in more extensive studies.
Some prescription drugs are used both in the treat-
ment of psychiatric disorders and for somatic diseases, 
e.g. antiepileptic medicine. Caution is warranted be-
cause of the uncertainty of data concerning the diagno-
sis of epilepsy and the prescription of antiepileptics.  
The subpopulations are defined by surrogate markers 
for mental illness.
Further studies are needed to identify the dual 
 diagnosis population among drug addicts in Denmark, 
including registry data to secure the diagnoses and fa-
cilitate the identification of morbidity and mortality risk 
factors within the group, and to establish the source of 
any prescription medication found in the blood of de-
ceased drug addicts
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72 (72.7) 12 (70.6) – – 84 (72.4) 46 (75.4) 15 (93.8) – – 61 (79.2)
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0.3 0.569
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0.349 0.024
